Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
Lisa A. Beck(University of Rochester Medicine), Brad Shumel(Regeneron (United States)), Marjolein de Bruin‐Weller(Netherlands Center for Occupational Diseases), Michihiro Hide(Hiroshima City Asa Citizens Hospital), Mette Deleuran(Aarhus University Hospital), Robert Bissonnette(Innovaderm (Canada)), Marius Ardeleanu(Regeneron (United States)), Bethany Beazley(Regeneron (United States)), Iftikhar Hussain(City University of Hong Kong), Neil M.H. Graham(UK Dementia Research Institute), Andrew Blauvelt(Veterans Health Administration), Diamant Thaçi(University of Lübeck), Lawrence Sher(Peninsula Research), Marcella Ruddy(Regeneron (United States)), Zhen Chen(Eunice Kennedy Shriver National Institute of Child Health and Human Development), Faisal A. Khokhar(Regeneron (United States)), Naimish Patel(Sanofi (United States))
Cited by 132
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k